当前位置: 首页 >> 检索结果
1101. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.
作者: S Zeuzem.;E Herrmann.;J H Lee.;J Fricke.;A U Neumann.;M Modi.;G Colucci.;W K Roth.
来源: Gastroenterology. 2001年120卷6期1438-47页
Covalent attachment of a 40-kilodalton polyethylene glycol moiety to interferon alpha2a (peginterferon alpha2a) results in sustained delivery and reduced clearance compared with standard interferon alpha2a. The aim of the study was to compare viral kinetics in patients treated with standard or peginterferon alpha2a.
1102. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease.
作者: K D Taylor.;S E Plevy.;H Yang.;C J Landers.;M J Barry.;J I Rotter.;S R Targan.
来源: Gastroenterology. 2001年120卷6期1347-55页
In the clinical trial, a lower response to infliximab was observed in some patients after multiple infusions, suggesting that clinical subgroups of Crohn's disease (CD) exist based on response to anti-tumor necrosis factor (anti-TNF). The aim of this study was to characterize these subgroups further by antineutrophil cytoplasmic antibody (ANCA) pattern and TNF genotype.
1103. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
作者: S Schreiber.;S Nikolaus.;H Malchow.;W Kruis.;H Lochs.;A Raedler.;E G Hahn.;T Krummenerl.;G Steinmann.; .
来源: Gastroenterology. 2001年120卷6期1339-46页
ISIS-2302, an antisense oligonucleotide directed against intercellular adhesion molecule 1, was effective in steroid refractory Crohn's disease in a pilot trial. The aim of this study was to investigate safety and efficacy of ISIS-2302 in chronic active Crohn's disease (CACD).
1104. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
作者: W J Sandborn.;B G Feagan.;S B Hanauer.;D H Present.;L R Sutherland.;M A Kamm.;D C Wolf.;J P Baker.;C Hawkey.;A Archambault.;C N Bernstein.;C Novak.;P K Heath.;S R Targan.; .
来源: Gastroenterology. 2001年120卷6期1330-8页
We evaluated CDP571, a humanized antibody to tumor necrosis factor, for the treatment of active Crohn's disease.
1105. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.
作者: G D'Haens.;L Lemmens.;K Geboes.;L Vandeputte.;F Van Acker.;L Mortelmans.;M Peeters.;S Vermeire.;F Penninckx.;F Nevens.;M Hiele.;P Rutgeerts.
来源: Gastroenterology. 2001年120卷6期1323-9页
Cyclosporine has been effective in patients with steroid-refractory attacks of ulcerative colitis (UC). We investigated the effects of intravenous (IV) cyclosporine as single IV therapy (without glucocorticosteroids) for severe UC and compared these with the response to glucocorticosteroids.
1106. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
作者: A J Sanyal.;C Campbell-Sargent.;F Mirshahi.;W B Rizzo.;M J Contos.;R K Sterling.;V A Luketic.;M L Shiffman.;J N Clore.
来源: Gastroenterology. 2001年120卷5期1183-92页
The pathogenesis of nonalcoholic steatohepatitis (NASH) is unknown. We tested the hypothesis that NASH is associated with 2 defects: (1) peripheral insulin resistance, which increases lipolysis, delivery of free fatty acids (FFA) to the liver, and hepatic fatty acid beta oxidation, thereby creating oxidative stress; and (2) an abnormality within the hepatocytes that might render them more susceptible to injury from oxidative stress.
1107. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans.
It is unclear whether fat digestion is required for the induction of gastrointestinal sensations and whether different fats have different effects. We investigated the effect of fat digestion and of medium-chain triglycerides (MCTs; C < 12) and long-chain triglycerides (LCTs; C > 16) on gastrointestinal sensations.
1108. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
作者: N J Wight.;K Gottesdiener.;N M Garlick.;C T Atherton.;S Novak.;B J Gertz.;N A Calder.;J Cote.;P Wong.;A Dallob.;C J Hawkey.
来源: Gastroenterology. 2001年120卷4期867-73页
Rofecoxib, an inhibitor of the inducible cyclooxygenase (COX)-2 enzyme, appears not to cause acute gastroduodenal injury or chronic ulceration. To attribute this to COX-2 selectivity with sparing of gastric mucosal prostaglandin synthesis requires direct proof.
1109. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.
作者: P B Jeppesen.;B Hartmann.;J Thulesen.;J Graff.;J Lohmann.;B S Hansen.;F Tofteng.;S S Poulsen.;J L Madsen.;J J Holst.;P B Mortensen.
来源: Gastroenterology. 2001年120卷4期806-15页
Glucagon-like peptide 2 (GLP-2) is intestinotrophic, antisecretory, and transit-modulating in rodents, and it is mainly secreted from the intestinal mucosa of the terminal ileum and colon after food ingestion. We assessed the effect of GLP-2 on the gastrointestinal function in patients without a terminal ileum and colon who have functional short-bowel syndrome with severe malabsorption of wet weight (>1.5 kg/day) and energy (>2.3 MJ/day) and no postprandial secretion of GLP-2.
1110. Efficacy and tolerability of racecadotril in acute diarrhea in children.
作者: J P Cézard.;J F Duhamel.;M Meyer.;I Pharaon.;M Bellaiche.;C Maurage.;J L Ginies.;J M Vaillant.;J P Girardet.;T Lamireau.;A Poujol.;A Morali.;J Sarles.;J P Olives.;C Whately-Smith.;S Audrain.;J M Lecomte.
来源: Gastroenterology. 2001年120卷4期799-805页
Oral rehydration therapy is the only treatment recommended by the World Health Organization in acute diarrhea in children. Antisecretory drugs available could not be used because of their side effects, except for racecadotril, which is efficient in acute diarrhea in adults.
1111. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension.
作者: A Escorsell.;J C Bandi.;V Andreu.;E Moitinho.;J C García-Pagán.;J Bosch.;J Rodés.
来源: Gastroenterology. 2001年120卷1期161-9页
Octreotide has been suggested for the treatment of variceal bleeding, but detailed dose-finding studies are not available. We performed a dose-finding study investigating the hemodynamic effects of several forms of intravenous octreotide administration.
1112. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis.
作者: A Bitton.;M A Peppercorn.;D A Antonioli.;J L Niles.;S Shah.;A Bousvaros.;B Ransil.;G Wild.;A Cohen.;M D Edwardes.;A C Stevens.
来源: Gastroenterology. 2001年120卷1期13-20页
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease. We aimed to assess whether clinical, biological, and histologic parameters in quiescent UC predict time to clinical relapse.
1113. Diagnosis of specialized intestinal metaplasia by optical coherence tomography.
作者: J M Poneros.;S Brand.;B E Bouma.;G J Tearney.;C C Compton.;N S Nishioka.
来源: Gastroenterology. 2001年120卷1期7-12页
Optical coherence tomography (OCT) is an imaging technique that produces high-resolution cross-sectional images in vivo. The aim of this study was to establish the sensitivity and specificity of OCT for diagnosing specialized intestinal metaplasia (SIM).
1114. Gallbladder muscle dysfunction in patients with chronic acalculous disease.
The mechanisms responsible for the abnormalities of gallbladder emptying in patients with chronic acalculous gallbladder disease (AGD) have not been elucidated. This study was designed to determine whether a muscle defect could explain this gallbladder dysfunction.
1115. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography.
作者: J Devière.;O Le Moine.;J L Van Laethem.;P Eisendrath.;A Ghilain.;N Severs.;M Cohard.
来源: Gastroenterology. 2001年120卷2期498-505页
Prophylactic administration of interleukin (IL)-10 decreases the severity of experimental pancreatitis. Prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in humans is a unique model to study the potential role of IL-10 in this setting.
1116. Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit.
作者: L P Degen.;F Peng.;A Collet.;L Rossi.;S Ketterer.;Y Serrano.;F Larsen.;C Beglinger.;P Hildebrand.
来源: Gastroenterology. 2001年120卷2期361-8页
This study was designed to characterize [D-F(5)Phe(6)D-Ala(11)]Bn(6-13)OMe (BIM26226) as a gastrin-releasing peptide (GRP)-preferring bombesin receptor antagonist and to determine whether GRP physiologically regulates gastrointestinal motility. Intravenous BIM26226 (5-500 microg. kg(-1). h(-1)) inhibits GRP-induced gallbladder contraction and plasma cholecystokinin (CCK) release in a dose-dependent fashion.
1117. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.
作者: E P Bouras.;M Camilleri.;D D Burton.;G Thomforde.;S McKinzie.;A R Zinsmeister.
来源: Gastroenterology. 2001年120卷2期354-60页
Prucalopride (PRU) is a selective benzofuran 5-hydroxytryptamine(4)-receptor agonist with gastrointestinal and colonic prokinetic activities. We evaluated the effects of PRU on gastrointestinal and colonic transit in patients with constipation.
1118. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.
作者: E Akriviadis.;R Botla.;W Briggs.;S Han.;T Reynolds.;O Shakil.
来源: Gastroenterology. 2000年119卷6期1637-48页
An earlier pilot study from our liver unit suggested benefit from treatment with pentoxifylline (PTX), an inhibitor of tumor necrosis factor (TNF), in severe acute alcoholic hepatitis. The aim of the present study was to evaluate this treatment in a larger cohort of patients.
1119. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
作者: R N Fedorak.;A Gangl.;C O Elson.;P Rutgeerts.;S Schreiber.;G Wild.;S B Hanauer.;A Kilian.;M Cohard.;A LeBeaut.;B Feagan.
来源: Gastroenterology. 2000年119卷6期1473-82页
Interleukin 10 (IL-10) is an anti-inflammatory, immunomodulatory cytokine that regulates mucosal inflammation. This study evaluated the safety, tolerance, and efficacy of recombinant human IL-10 (rhuIL-10) for mild to moderately active Crohn's disease.
1120. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
作者: S Schreiber.;R N Fedorak.;O H Nielsen.;G Wild.;C N Williams.;S Nikolaus.;M Jacyna.;B A Lashner.;A Gangl.;P Rutgeerts.;K Isaacs.;S J van Deventer.;J C Koningsberger.;M Cohard.;A LeBeaut.;S B Hanauer.
来源: Gastroenterology. 2000年119卷6期1461-72页
Interleukin (IL)-10 is a cytokine with potent anti-inflammatory properties. We investigated the safety and efficacy of different doses of human recombinant (rhu)IL-10 in patients with Crohn's disease (CD).
|